Benefits of the 2nd comparative study have been claimed by Flinn et al. This can be a stage III randomized Intergroup demo evaluating FC routine vs . FAMP alone in 278 patients getting their initially chemotherapy program for B-CLL. Dosages of FC program had been the same as the primary https://lennyl531ddc0.bloggerchest.com/profile